Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No clinical trials have been registered for indolent primary cutaneous B-cell lymphoma.
5 publications have been identified in PubMed for indolent primary cutaneous B-cell lymphoma. Research spans Other (20%), Review / Meta-Analysis (20%), and Clinical Trial Publication (20%).
Alì E (2026). [PMID: 41391721](https://pubmed.ncbi.nlm.nih.gov/41391721/). *Radiother Oncol*. [Epidemiology / Natural History]
Griss J (2026). [PMID: 41639106](https://pubmed.ncbi.nlm.nih.gov/41639106/). *Nat Commun*. [Basic Science / Preclinical]
Oertel M (2026). [PMID: 41824381](https://pubmed.ncbi.nlm.nih.gov/41824381/). *Blood*. [Clinical Trial Publication]
Quintanilla-Martinez L (2025). [PMID: 40616614](https://pubmed.ncbi.nlm.nih.gov/40616614/). *Virchows Arch*. [Review / Meta-Analysis]
Fassanaro C (2025). [PMID: 40340188](https://pubmed.ncbi.nlm.nih.gov/40340188/). *Therapie*. [Other]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:06 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning indolent primary cutaneous B-cell lymphoma
Updated Feb 4, 2026
Recent research indicates that indolent primary cutaneous B-cell lymphomas exhibit characteristics similar to persistent antigen reactions, lacking signs of dedifferentiation. This finding may influence future diagnostic and therapeutic strategies for this rare lymphoma subtype.